Scythian Biosciences (SCYB) Stock Price, News & Analysis

Company Overview

Scythian Biosciences Corp. engages in the research and development of cannabinoid-based combination drug therapies for the treatment of concussions and traumatic brain injury. It also develops drug candidates for the treatment of gastro-intestinal inflammatory issues. The company is headquartered in Toronto, Canada.

Key Stats

• Today's Range: C$3.46 to C$3.77
• 50-Day Range: C$3.49 to C$3.49
• 52-Week Range: C$1.01 to C$8.61
• Volume: 703,164 shs
• Average Volume: 231,491 shs
• Market Capitalization: C$102.38 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SCYB Stock Analysis - Frequently Asked Questions

How have SCYB shares performed this year?

Scythian Biosciences' stock was trading at C$3.49 at the beginning of 2025. Since then, SCYB shares have increased by 0.0% and is now trading at C$3.49.

How do I buy shares of Scythian Biosciences?

Shares of SCYB stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What other stocks do shareholders of Scythian Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Scythian Biosciences investors own include DraftKings (DKNG), Lithium South Development Co. (NGZ.V) (NGZ), Organigram (OGI), Scythian Biosciences (SCCYF), SOL Global Investments (SOLCF), CanniMed Therapeutics (CMED) and Compugen (CGEN).

Industry, Sector and Symbol

• Stock Exchange: CVE
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: CVE:SCYB
• CIK: N/A
• Web: scythianbio.com
• Phone: +1-416-3669192
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 29,334,000
• Free Float: N/A
• Market Cap: C$102.38 million
• Optionable: Not Optionable
• Beta: N/A